While there are arguments that insulin therapy could increase the risk of CVD in type 2 DM, the increased risk of CVD in insulin users and those taking ≥ 3 oral GLDs suggests that insulin use should be interpreted as a marker of diabetes progression or severity. The gene discussed is INS; the disease is diabetes mellitus.